Level Biotechnology (Taiwan) Performance
| 3118 Stock | TWD 32.10 0.05 0.16% |
The company secures a Beta (Market Risk) of 0.11, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Level Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Level Biotechnology is expected to be smaller as well. At this point, Level Biotechnology has a negative expected return of -0.0446%. Please make sure to verify Level Biotechnology's total risk alpha, maximum drawdown, skewness, as well as the relationship between the treynor ratio and potential upside , to decide if Level Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Level Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Level Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 380.3 M | |
| Total Cashflows From Investing Activities | -8.8 M |
Level |
Level Biotechnology Relative Risk vs. Return Landscape
If you would invest 3,305 in Level Biotechnology on August 31, 2024 and sell it today you would lose (95.00) from holding Level Biotechnology or give up 2.87% of portfolio value over 90 days. Level Biotechnology is generating negative expected returns and assumes 0.7082% volatility on return distribution over the 90 days horizon. Simply put, 6% of stocks are less volatile than Level, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Level Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Level Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Level Biotechnology, and traders can use it to determine the average amount a Level Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0629
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 3118 |
Estimated Market Risk
| 0.71 actual daily | 6 94% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Level Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Level Biotechnology by adding Level Biotechnology to a well-diversified portfolio.
Level Biotechnology Fundamentals Growth
Level Stock prices reflect investors' perceptions of the future prospects and financial health of Level Biotechnology, and Level Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Level Stock performance.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0519 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 489.43 M | |||
| Shares Outstanding | 32.45 M | |||
| Price To Earning | 22.00 X | |||
| Price To Book | 1.71 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 677.28 M | |||
| EBITDA | 105.06 M | |||
| Cash And Equivalents | 295.07 M | |||
| Cash Per Share | 9.09 X | |||
| Total Debt | 18.11 M | |||
| Debt To Equity | 3.50 % | |||
| Book Value Per Share | 16.16 X | |||
| Cash Flow From Operations | 155.95 M | |||
| Earnings Per Share | 1.74 X | |||
| Total Asset | 787.62 M | |||
About Level Biotechnology Performance
Evaluating Level Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Level Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Level Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Level Biotechnology Inc. markets and distributes cell culture, immunology, molecular biology products and biomedical precision equipment in Taiwan. The company was founded in 1989 and is headquartered in New Taipei City, Taiwan. LEVEL BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 122 people.Things to note about Level Biotechnology performance evaluation
Checking the ongoing alerts about Level Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Level Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Level Biotechnology generated a negative expected return over the last 90 days | |
| About 32.0% of the company shares are owned by insiders or employees |
- Analyzing Level Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Level Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Level Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Level Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Level Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Level Biotechnology's stock. These opinions can provide insight into Level Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Level Stock Analysis
When running Level Biotechnology's price analysis, check to measure Level Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Level Biotechnology is operating at the current time. Most of Level Biotechnology's value examination focuses on studying past and present price action to predict the probability of Level Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Level Biotechnology's price. Additionally, you may evaluate how the addition of Level Biotechnology to your portfolios can decrease your overall portfolio volatility.